EA201690951A1 - Мякрнк, композиции и применения - Google Patents
Мякрнк, композиции и примененияInfo
- Publication number
- EA201690951A1 EA201690951A1 EA201690951A EA201690951A EA201690951A1 EA 201690951 A1 EA201690951 A1 EA 201690951A1 EA 201690951 A EA201690951 A EA 201690951A EA 201690951 A EA201690951 A EA 201690951A EA 201690951 A1 EA201690951 A1 EA 201690951A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- snornas
- aging
- relates
- individual
- well
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 abstract 5
- 102000042773 Small Nucleolar RNA Human genes 0.000 abstract 5
- 230000032683 aging Effects 0.000 abstract 3
- 230000007246 mechanism Effects 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 208000026585 laminopathy Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/148—Screening for cosmetic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
Abstract
Настоящее изобретение относится к применению конкретных последовательностей РНК в качестве лекарственного средства. Более конкретно оно относится к применению малых ядрышковых РНК (мякРНК), для которых авторы изобретения продемонстрировали участие в механизмах старения. мякРНК по изобретению можно использовать в частности для повышения устойчивости к стрессу индивидуума, для борьбы с неблагоприятными эффектами старения, как правило, для профилактики или лечения дегенеративного заболевания, ламинопатии, диабета, ожирения или злокачественной опухоли, а также в более широком смысле для увеличения продолжительности жизни индивидуума. мякРНК по изобретению также можно использовать при лечении бесплодия. Изобретение также относится к векторам, клеткам, трансгенным животным и композициям, способным экспрессировать мякРНК по изобретению, а также к способам, в которых используют один из указанных выше продуктов по изобретению, таких как средство идентификации молекулы, которая является активной для профилактики или лечения патологии, аномалии или нарушения, связанного с механизмом старения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1360889A FR3012739A1 (fr) | 2013-11-07 | 2013-11-07 | Sno arn, compositions et utilisations |
PCT/EP2014/073991 WO2015067727A1 (fr) | 2013-11-07 | 2014-11-07 | Sno arn, compositions et utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690951A1 true EA201690951A1 (ru) | 2016-10-31 |
EA037923B1 EA037923B1 (ru) | 2021-06-07 |
Family
ID=51871027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690951A EA037923B1 (ru) | 2013-11-07 | 2014-11-07 | мякРНК, КОМПОЗИЦИИ И ПРИМЕНЕНИЯ |
Country Status (17)
Country | Link |
---|---|
US (1) | US9951332B2 (ru) |
EP (1) | EP3066199B1 (ru) |
JP (2) | JP6879738B2 (ru) |
KR (1) | KR102269438B1 (ru) |
CN (1) | CN106232816B (ru) |
AU (1) | AU2014345581B2 (ru) |
BR (1) | BR112016010342B1 (ru) |
CA (1) | CA2929732A1 (ru) |
DK (1) | DK3066199T3 (ru) |
EA (1) | EA037923B1 (ru) |
ES (1) | ES2671326T3 (ru) |
FR (1) | FR3012739A1 (ru) |
HU (1) | HUE037525T2 (ru) |
NO (1) | NO3066199T3 (ru) |
PT (1) | PT3066199T (ru) |
TR (1) | TR201807186T4 (ru) |
WO (1) | WO2015067727A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3012739A1 (fr) * | 2013-11-07 | 2015-05-08 | Centre Nat Rech Scient | Sno arn, compositions et utilisations |
CN112020557A (zh) * | 2018-03-27 | 2020-12-01 | 罗切斯特大学 | 用于假尿苷化的核酸分子 |
CN111826432A (zh) * | 2019-04-18 | 2020-10-27 | 南京大学 | 细胞去服务化状态的分子标记物检测及其调控方法 |
WO2021175966A1 (en) | 2020-03-04 | 2021-09-10 | Ninovax | Products for suppressing or reducing the expression or activity of a snorna and uses thereof in the treatment of cancer |
CN116694759B (zh) * | 2023-02-17 | 2023-12-15 | 中国人民解放军军事科学院军事医学研究院 | Scarna12基因调节细胞增殖与存活中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268749A1 (en) | 1996-10-21 | 1998-04-30 | Mcgill University | Structural and functional conservation of the c. elegans clock gene clk-1 |
US6303768B1 (en) | 1998-08-07 | 2001-10-16 | California Institute Of Technology | Methuselah gene, compositions and methods of use |
FR2882062B1 (fr) | 2005-02-14 | 2007-06-15 | Commissariat Energie Atomique | Vecteurs d'expression stable et de longue duree de sirna et leurs applications |
FR3012739A1 (fr) * | 2013-11-07 | 2015-05-08 | Centre Nat Rech Scient | Sno arn, compositions et utilisations |
-
2013
- 2013-11-07 FR FR1360889A patent/FR3012739A1/fr not_active Withdrawn
-
2014
- 2014-11-07 US US15/035,327 patent/US9951332B2/en active Active
- 2014-11-07 CN CN201480066854.8A patent/CN106232816B/zh active Active
- 2014-11-07 DK DK14796053.8T patent/DK3066199T3/en active
- 2014-11-07 ES ES14796053.8T patent/ES2671326T3/es active Active
- 2014-11-07 HU HUE14796053A patent/HUE037525T2/hu unknown
- 2014-11-07 BR BR112016010342-4A patent/BR112016010342B1/pt active IP Right Grant
- 2014-11-07 EP EP14796053.8A patent/EP3066199B1/fr active Active
- 2014-11-07 JP JP2016528185A patent/JP6879738B2/ja active Active
- 2014-11-07 TR TR2018/07186T patent/TR201807186T4/tr unknown
- 2014-11-07 PT PT147960538T patent/PT3066199T/pt unknown
- 2014-11-07 KR KR1020167015086A patent/KR102269438B1/ko active IP Right Grant
- 2014-11-07 NO NO14796053A patent/NO3066199T3/no unknown
- 2014-11-07 AU AU2014345581A patent/AU2014345581B2/en active Active
- 2014-11-07 EA EA201690951A patent/EA037923B1/ru unknown
- 2014-11-07 CA CA2929732A patent/CA2929732A1/fr active Pending
- 2014-11-07 WO PCT/EP2014/073991 patent/WO2015067727A1/fr active Application Filing
-
2019
- 2019-09-18 JP JP2019169733A patent/JP2020010707A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2671326T3 (es) | 2018-06-06 |
EA037923B1 (ru) | 2021-06-07 |
TR201807186T4 (tr) | 2018-06-21 |
CN106232816A (zh) | 2016-12-14 |
US9951332B2 (en) | 2018-04-24 |
EP3066199A1 (fr) | 2016-09-14 |
WO2015067727A1 (fr) | 2015-05-14 |
BR112016010342B1 (pt) | 2023-01-31 |
HUE037525T2 (hu) | 2018-09-28 |
JP6879738B2 (ja) | 2021-06-02 |
AU2014345581B2 (en) | 2021-03-11 |
JP2017502650A (ja) | 2017-01-26 |
AU2014345581A1 (en) | 2016-06-23 |
JP2020010707A (ja) | 2020-01-23 |
KR102269438B1 (ko) | 2021-06-24 |
US20160298112A1 (en) | 2016-10-13 |
FR3012739A1 (fr) | 2015-05-08 |
PT3066199T (pt) | 2018-06-05 |
KR20160079112A (ko) | 2016-07-05 |
CN106232816B (zh) | 2021-08-06 |
BR112016010342A2 (pt) | 2017-12-12 |
NO3066199T3 (ru) | 2018-08-18 |
DK3066199T3 (en) | 2018-06-06 |
CA2929732A1 (fr) | 2015-05-14 |
EP3066199B1 (fr) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018006590A2 (es) | Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1 | |
EA201792263A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201690951A1 (ru) | Мякрнк, композиции и применения | |
CO2017000357A2 (es) | Ácidos nucleicos antisentido | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA201790789A1 (ru) | Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы)) | |
EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
EA201990644A1 (ru) | Антисмысловые олигонуклеотиды для лечения глазного заболевания | |
EA201890571A1 (ru) | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) | |
EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
WO2016209862A8 (en) | Glucokinase (gck) irna compositions and methods of use thereof | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
MX2019008380A (es) | Composiciones de arni contra el componente c5 del complemento y metodos para su uso. | |
CO2019003846A2 (es) | Tratamiento aav de la enfermedad de huntington | |
NZ733882A (en) | Compositions for modulating c9orf72 expression | |
EA201591992A1 (ru) | Эффективная доставка больших генов посредством двойных aav векторов | |
EA201592223A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201591792A1 (ru) | Улучшенные композиции для лечения мышечной дистрофии | |
EA201491953A1 (ru) | СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21 | |
EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
CR20210393A (es) | COMPOSICIONES DE AGENTE DE ARNi DE PROTEÍNA PRECURSORA DE AMILOIDE (APP) Y MÉTODO DE USO DE LAS MISMAS | |
EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина |